×

Leadership Corporate Leaders

  • Even in this treacherous market, good execution pays off, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • gsk_logo.jpg

    Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.

  • While housing pulls down the rest of the market, Mike Farrell's pulling in profits. Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • housing_builders.jpg

    I don’t often get to chat with the CEOs of the big public builders anymore. Most of them can’t stand me because they think I’m to blame for the downfall of the housing market (What? Is my middle name Mozilo or something???).

  • biogenidec_AP.jpg

    I'm blogging a little later than usual because I got sidetracked by the breaking news on the government stopping part of a big diabetes drug study over safety concerns--more people died in a group that was being intensively treated to get their blood sugar levels below current recommendations.

  • graphic_fast_money.jpg

    Disney reported earnings Tuesday that blew past forecasts and sent the stock screaming higher in after-hours trading. CNBC’s Julia Boorstin sat down with Disney CEO Bob Iger in an exclusive post-earnings interview to find out what is driving growth at the Mouse House.

  • Cramer's 2007 growth stock of the year has been a major disappointment, so he brought the chief executive on the show to find out what's going on.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • boston_scientific.jpg

    Sales of drug-coated stents, Boston Scientific's most profitable products, came in at the low end of the company's guidance in the fourth quarter. Stents are the fragile little wire mesh cylinders that act like scaffolding to prop open clogged arteries.

  • General Electric said Friday that vice chairman Bob Wright, former head of the company's NBC arm, will retire on May 1.

  • A new merger and growth overseas make this stock a buy.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Investors have a chance to pick up a great long-term investment on the cheap, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • google_nonumber.jpg

    Google's earnings and sales both rose but fell short of analyst expectations, and shares of the company fell in extended trading.

  • colligan_ed.jpg

    Even as Apple Inc. tries to fend off rumors that iPhone sales are slowing, and Nokia generates a flood of positive media because of better than expected sales this past quarter, struggling Palm continues to raise its hand, trying to get noticed amid all the action in the wireless sector.

  • The CEO explains why his company is the ultimate slowdown stock.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • DanielBouton_SocGenChairman.jpg

    Scandal-hit French bank Societe Generale opened its own inquiry on Wednesday into how it suffered history's biggest rogue trader loss, but resisted heavy pressure to sack its chairman and CEO.

  • steve_jobs_airbook.jpg

    If you think your portfolio has taken a hit since the beginning of the year, consider Steve Jobs and his stake in Apple: He's down $377 million and change since Jan. 1, so if anyone knows the magnitude of Apple's steep--and some say overdone--decline since then, it's the mercurial Apple chief.

  • Byetta Needle

    Direct-to-consumer pharmaceutical advertising is everywhere in American media because it works. Generally speaking, it drives patients to ask/tell their doctors to prescribe a particular medication.

  • The Phillips-Van Heusen CEO explains why his company should make the cut. Plus, Jim's favorite names in the sector.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.